Costing Details

Inpatient costs were estimated in UK£ at 2013/14 prices from published NHS sources at a mean cost of £513 per day for non-elective admissions for liver disease.1

Rifaximin-α drug costs were calculated from the price published in the British National Formulary of £259.23 for 56 550mg tablets2, giving an annual drug treatment cost per patient of £3,379 for the licensed dose of 550mg twice daily.

 

References

  1. NHS reference costs. Available from: www.gov.uk/government/publications/nhs-reference-costs-2013-to-2014, 2013-14
  2. Joint Formulary Committee. British National Formulary. August 2015 ed. London: BMJ Group and Pharmaceutical Press; 2015
Seven UK participating centres agreed a standardised data collection pro-forma. Patients with chronic liver disease who were treated with rifaximin-α for secondary prevention of overt hepatic encephalopathy (OHE) were included.* Details of all causes of HE and emergency hospital admissions were requested at 3, 6 and 12 months before and after rifaximin-α initiation. Clinical data were recorded at baseline, at 3, 6 and 12 months before and after rifaximin-α initiation.
87% of patients (n=282) were taking concomitant lactulose.
*Some patients included were on 3 x 400 mg daily as this was prior to the launch of the UK licensed dose of TARGAXAN® 550 mg twice a day.

References

  1. Orr J G, Currie C J et al. Liver Int 2016;36:1295-1303
  2. Hudson M, et al. Frontline Gastroenterology. Published Online First: 07-April-2017. doi:10.1136/flgastro-2016-100792
  3. Hudson M, et al. Frontline Gastroenterology. Published Online First: 07-April-2017. doi:10.1136/flgastro-2016-100792 Supplementary Material